Results 121 to 130 of about 27,144 (229)

Podocyte puzzle: IgA nephropathy

open access: yesClinical Kidney Journal, 2023
Joyita Bharati   +2 more
openaire   +2 more sources

Unveiling the immune landscape and microenvironmental architecture of IgA nephropathy using single‐cell imaging mass cytometry

open access: yesClinical &Translational Immunology, Volume 15, Issue 3, March 2026.
In IgA nephropathy (IgAN), innate and adaptive immune cells display distinct spatial compartmentalisation, with macrophages predominating within glomeruli and CD4+ T cells constituting the major immune population in inflammatory foci. Glomeruli with distinct pathological morphologies exhibit morphology‐dependent immune infiltration patterns and ...
Xing Chen   +8 more
wiley   +1 more source

Potential neuroprotective and therapeutic agents and their mechanisms for irradiation‐induced brain injury

open access: yesIbrain, Volume 12, Issue 1, Page 96-122, Spring 2026.
In this review, agents such baicalein, troxerutin, epigallocatechin gallate, quercetin, melatonin, valproic acid, lithium, neurosteroid progesterone, as well as minocycline have been implicated as neuroprotective agents for irradiation‐induced neurological deficits. Also, agents such as glucocorticoids, methylphenidate, vitamin E, bisdemethoxycurcumin,
Seidu A. Richard   +2 more
wiley   +1 more source

Podocyte‐Derived Extracellular Vesicles Induce Endothelial Dysfunction by Triggering ER Stress in Glomerular Disease

open access: yesJournal of Extracellular Vesicles, Volume 15, Issue 3, March 2026.
ABSTRACT Podocyte injury and endothelial cell dysfunction are the hallmarks of glomerular disease. How these two events are connected remains largely unknown. This study aimed to delineate the role of extracellular vesicles (EVs) in mediating podocyte‐endothelial communication in glomerular disease.
Zhao Liu   +10 more
wiley   +1 more source

Remodeling the Inflammatory Microenvironment: Nanomaterial‐Based Targeted Strategies for Systemic Lupus Erythematosus and Lupus Nephritis

open access: yesSmall Science, Volume 6, Issue 3, March 2026.
Current treatments for severe lupus nephritis are limited by side effects due to poor drug targeting. This review explores how smart nanomaterials—like liposomes and biomimetic carriers—can precisely deliver drugs to overactive immune cells and the kidneys. These nanotherapeutics enhance efficacy, reduce toxicity, and enable combination strategies. The
Cheng Zhou   +6 more
wiley   +1 more source

The Interaction Between Mitophagy Dysregulation and the Diabetic Bladder Microenvironment

open access: yesJournal of Diabetes, Volume 18, Issue 3, March 2026.
Hyperglycemia suppresses the PINK1/Parkin pathway, impairing mitophagy and triggering ROS accumulation. This activates NLRP3 inflammasome and AGEs‐RAGE axis, driving bladder inflammation and fibrosis. A bidirectional positive feedback loop forms between mitophagy dysregulation and microenvironment deterioration, accelerating diabetic bladder ...
Shi Li   +4 more
wiley   +1 more source

WDR72 Is Required for Urinary Acidification and Normal H+‐ATPase Activity in Intercalated Cells in Mice

open access: yesActa Physiologica, Volume 242, Issue 3, March 2026.
ABSTRACT Aim Biallelic inactivating WDR72 variants are linked to distal renal tubular acidosis (dRTA), nephrocalcinosis, and amelogenesis imperfecta. The kidney shows high WDR72 expression; its precise localization and function remain unclear. WDR72 is a member of the WD40 repeat domain protein family—a large group of scaffold proteins involved in ...
Hannah Auwerx   +4 more
wiley   +1 more source

Association Between NHHR and Future Cardiovascular Disease Among Patients With CKM Stages 0–3: A Nationwide Prospective Cohort Study

open access: yesThe Journal of Clinical Hypertension, Volume 28, Issue 3, March 2026.
ABSTRACT The American Heart Association recently proposed the concept of Cardiovascular‐kidney‐metabolic (CKM) syndrome, emphasizing the interconnections among cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic disorders. The ratio of non‐high‐density lipoprotein cholesterol to high‐density lipoprotein cholesterol (NHHR) has ...
Yu Huang   +6 more
wiley   +1 more source

Linderalactone mitigates diabetic renal injury by inhibiting macrophage inflammation via the Dectin1/Syk/CARD9/IRF5/NF‐κB pathway

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 3, Page 395-410, March 2026.
ABSTRACT Background Inflammation plays an essential role in the pathogenesis of diabetic nephropathy (DN). Linderalactone (LNL), as a natural sesquiterpene lactone, has been discovered to have anti‐inflammatory activation. However, the effects of linderalactone on diabetes‐associated renal damage remain unclear.
Hao Chen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy